At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity
In Brief
A Phase 1 clinical trial evaluating Tirzepatide and Placebo for Obesity. Completed, enrolled 28 participants across 3 sites.
Detailed Summary
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedJan 2023
Enrollment StartFeb 2023
Primary CompletionJan 2025
TodayJul 2026
First PostedJan 25, 2023
Enrollment StartFeb 7, 2023
Primary CompletionJan 16, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.4 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC